2020 Annual Conference   |   Postponed

Important Annual Conference Update

In light of the rapid global changes in connection with COVID-19, our community of medical professionals and our lab-based researchers are being called upon to prepare for the possibility of a significant influx of critically ill patients needing treatment at their hospitals and institutions. Our industry partners are also directly involved in combatting this unprecedented global health crisis. In consultation with the Conference Chairs, Advisory Board Members and the Board of Directors, the decision has been made to postpone the 2020 Cholangiocarcinoma Foundation Virtual Conference scheduled for April 1-3, 2020.

It is our desire to bring you an interactive virtual conference which we cannot do without the active participation of our professional community who are currently engaged in keeping you, and our communities, safe. In order to best support them, until this crisis is mitigated, we have postponed the conference until later this year so that our entire research community can participate.

In the meantime, please keep the people affected by COVID-19 and the medical professionals on the frontlines of this pandemic in your thoughts and prayers. We are deeply indebted to these healthcare providers for the work that they are doing to help their communities and our global community during this unprecedented time. Please watch our website and social media platforms for COVID-19 information specific to cancer patients and their families.

We will keep you updated on the virtual conference when we have dates and details to share. Please be assured that we will continue working with our professional community and sponsors on the conference planning behind the scenes to ensure that it is a fantastic event in which the entire community can participate.

If you have any questions, please don't hesitate to reach out, info@cholangiocarcinoma.org

April 1 - 3, 2020
Salt Lake City, Utah, USA

Coming Soon

Conference Chairs
<b>Jesús M Banales, PhD</b><br/>
Biodonostia Institute<br/>San Sebastián, Spain
Jesús M Banales, PhD
Biodonostia Institute
San Sebastián, Spain
<b>Rachna T Shroff, MD, MS</b><br/>
University of Arizona Cancer Center<br/>Tucson, Arizona, USA
Rachna T Shroff, MD, MS
University of Arizona Cancer Center
Tucson, Arizona, USA

2020 Cholangiocarcinoma Foundation Annual Conference

The 2020 Conference will build upon the foundation laid at this year’s meeting as key opinion leaders both nationally and internationally, come together to collaborate and exchange knowledge. The program will seek to develop sustainable participation of the medical and research communities in the field of cholangiocarcinoma by:


Increasing the knowledge and understanding of attendees about key issues central to the prevention, diagnosis, treatment, and cure for cholangiocarcinoma

A New Perspective

Identifying gaps and gathering consensus on rapidly changing advances in basic, translational, and clinical research


Stimulating interdisciplinary cross-cooperation and sharing best practices by developing, strengthening, and supporting collaborations


Fostering dialogue and inspiring innovation across the world

Further, because patients living with cholangiocarcinoma have a direct stake in their own medical care and are in a unique position to provide input, CCF has expanded its Annual Conference to include programming that addresses questions and concerns that are important to patients and their families. Patients and caregivers—having experienced the disease firsthand—will be invited to learn about cholangiocarcinoma, share their personal experiences, and contribute to future efforts to further cholangiocarcinoma research.

Who Should Attend?

Who Should Attend?

  • Researchers
  • Physicians
  • Oncologists
  • Radiologists
  • Surgeons
  • Gastroenterologists
  • Hepatologists
  • Nurses specializing in oncology, intensive care, and palliative care
  • Pharmaceutical Companies
  • Government Regulators
  • Policymakers
  • Patients, Caregivers and others invested in the field of cholangiocarcinoma

Frequently Asked Questions

Incredible Numbers from our 2019 Conference


from 40 states and 12 countries representing healthcare, industry, patient advocacy organizations, patients, caregivers, academia and supporters.


including those by researchers, surgeons, patients, caregivers and industry specialists.


Medical Institutions

represented, including international key opinion leaders advancing cholangiocarcinoma research, treatment and care.


  • 200+ patients/caregivers
  • 29 poster presentations
  • 1,612 webcast attendees

with support from

  • 30 organizations: Agios, ASLAN Pharmaceuticals, Basiliea
    Pharmaceutica, Bayer, Beigene, Boston-Scientific, Bristol-Myers Squibb, Caris Life Sciences, Daiichi-Sankyo, DebiopharmGroup, EMD Serono, Foundation Medicine, Fujifilm, Incyte, Halozyme, Klus Pharma, Leap Therapeutics, Lexicon Pharmaceuticals, Merck, MundiPharma, NuCana, PCI Biotech, Pieris Pharmaceuticals, QED Therapeutics, RedHill Biopharma, Shepherd Therapeutics, Sirtex, Taiho Oncology, TriSalus Life Sciences, Zymeworks.

Thanks to these sponsors, we are able to bring our conference to you...live and on demand.

Sequoia Level

Oak Level

Cedar Level

Maple Level

Funding for this conference was made possible (in part) by 1R13CA246934 from the National Cancer Institute. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.